Ifetroban

未知生产厂商

Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

技术标识符

化学式: C₂₅H₃₂N₂O₅
CAS 编号: 143443-90-7
UNII ID: E833KT807K

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

COMPOSITIONS AND METHODS OF TREATING SYSTEMIC SCLEROSIS OR PULMONARY ARTERIAL HYPERTENSION
EP 3804717 A1申请人: CUMBERLAND PHARMACEUTICALS INC优先权: 2014
CN
EP
US
7 件公开
Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists
US 2008261922 A1申请人: CARLEY DAVID W优先权: 2005
US
WO
3 件公开
Ifetroban Treatment for Systemic Sclerosis
US 20250114334 A1申请人: CUMBERLAND PHARMACEUTICALS INC优先权: 2016
CN
US
2 件公开
Methods of inhibiting tumor metastasis
US 11471444 B2申请人: UNIV VANDERBILT优先权: 2018
US
2 件公开
Compositions and methods of treating cardiac fibrosis with ifetroban
US 12161632 B2申请人: CUMBERLAND PHARMACEUTICALS INC优先权: 2023
US
2 件公开
Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US 2003109543 A1申请人: OGLETREE MARTIN L优先权: 2002
US
METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19
EP 4125882 A4申请人: OGLETREE MARTIN优先权: 2020
EP

药物